Stomach Cancer Clinical Trials & Research

MSK is a major research institution. During your treatment for stomach cancer, your care team may ask if you want to join a clinical trial.

What is a clinical trial?

Clinical trials are research studies that test new treatments, procedures, or devices to see how well they work. They are an important part of helping to prevent, treat, and cure cancer. Almost every cancer treatment given to patients was first tested during a clinical trial.

MSK tests new treatments for stomach cancer. Treatment trials test new drugs, drug combinations, devices, and ways of doing procedures, surgery, or radiation therapy.

Sometimes a clinical trial gives you access to new therapies that are not yet available at most hospitals. Talk with your doctor about whether joining a clinical trial is right for you.

Clinical trials are designed to answer questions about:

  • Safety
  • Benefits
  • Side effects
  • Whether some people are helped more than others

MSK will start a clinical trial only if our researchers think we can improve methods for cancer:

  • Prevention
  • Treatment
  • Diagnosis
  • Screening

For more information, please read Clinical Trials at MSK: What You Need to Know.

Clinical trials you may be able to join

MSK is researching better ways to identify what can raise the risk of getting gastric cancer. We’re gathering important information in a research project. You may be able to join our Hereditary Gastric Cancer Registry and Gastric Precursor Registry.

You may be able to join clinical trials. You can see a current listing of MSK’s clinical trials for stomach cancer below.

Currently Enrolling

To learn more about a study, choose from the list below.

and/or
21 Clinical Trials found
A Phase 1b-2 Study of ZL-1310 in People With Gastroenteropancreatic Neuroendocrine Cancers
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of AgenT-797 Plus Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancers
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of AZD0901 and Rilvegostomig Plus Standard Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Researchers want to see if combining AZD0901 and rilvegostomig with standard chemotherapy works well in people with gastric or gastroesophageal junction (GEJ) cancer. GEJ cancer occurs where the esophagus joins the stomach.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Pembrolizumab Immunotherapy With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Researchers are assessing the use of multiple medications given before surgery to treat esophagogastric cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that can be taken out (operable). In addition, their cancers make a protein called HER2.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of AZD0901 Versus Standard Therapy to Treat Advanced Stomach or Gastroesophageal Junction Cancer With Claudin18.2
Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Trastuzumab Deruxtecan Plus Chemotherapy With or Without Pembrolizumab Versus Trastuzumab Plus Chemotherapy With or Without Pembrolizumab in People With Gastric or Gastroesophageal Junction Cancers
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I Study of TJ033721 Immunotherapy in People with Advanced Pancreatic or Esophagogastric Cancer
The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase IB/II Study of Trastuzumab Deruxtecan in People with Advanced Gastric Cancer or Gastroesophageal Junction Cancer
Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase III Study Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
The purpose of this study is to compare proton beam radiation therapy with intensity-modulated radiation therapy (IMRT) in patients with stage I-IVA esophageal cancer. Both approaches send radiation inside the body to a tumor without damaging much of the healthy tissue around it. However, proton beam radiation therapy uses protons while IMRT uses photons (high-energy x-rays).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of Drug Combinations Before and After Surgery in People With Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancer
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau